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Objective: The present study was aimed to monitor the prognostic response of antiretroviral therapy in HIV 
positive patients.  
Methodology: The study was conducted on confirmed HIV positive patients registered at HIV treatment and care 
centre, PIMS. Islamabad from January 2013 to December 2015. Among all HIV positive patients, 276 adult cases 
were selected. There were 263 patients on first-line antiretroviral (ARV) therapy and 13 patients were shifted to 
2nd line ARV therapy. CD4 cell counts and viral load (Polymerase chain reaction) monitoring was done after one 
year of starting ARV therapy.  
Results: Out of 276 adult patients,  75% (n=207) were male and 25% (n=69) were females. Among 276 adult cases, 
95.3% (n=263) patients were on first line ARV therapy. Patients on first line ARV therapy showed good prognostic 
response. There  were 15.5% (n=40) patients having  CD4+cells less than 350 cells/µL. There were 84.5% (n=223) 
patients having  CD4 +cells count greater than 350 cells/µL There were 69% (n=182) patients having viral load 
<50 copies/ml and 31% (n=81) patients who had viral load >50 copies/ml.  
Conclusion: First line ARV therapy given to HIV positive patients proved itself best both in respect of increasing 
the immunity of HIV positive patients by increasing the number of CD4 cells and also results in effective viral 
load suppression. 
Keywords: Antiretroviral therapy, CD4+ cells, HIV patients. 




Human immunodeficiency virus is responsible to 
cause HIV infection and Acquired Immunodeficiency 
Syndrome (AIDS), thus people with AIDS are at a very 
high risk of acquiring multiple infections, cancers, and 
other AIDS-related complications. HIV testing and 
counseling is the first crucial step for linkage to HIV 
treatment and prevention. When HIV infection 
proceeds, CD4 cell count starts to decline. At present, 
CD4 cell count is considering a strong predictor of 
monitoring the risk of AIDS. When HIV positive 
patients have CD4 cell count below 250cells/ml, 
antiretroviral therapy is going to be initiated.1 
CD4 cell count has given central importance in 
deciding ARV initiation, ARV switching, and 
managing opportunistic infections timely. Immunity in 
HIV positive patients will decline continuously when 
their CD4 cell count falls below 200 cells/ml and ARVs 
have not been initiated yet.2 
In a study conducted in South Africa, HIV positive 
patients had given ARVs at a CD4 cell count of 200 
cells/ml and 92% of patients showed a good 
prognostic response. The same findings had been 
shown in the Uganda cohort study. These patients also 
showed viral load suppression with CD4cell count > 
200 cells/mm.3,4 
Polymerase Chain Reaction (PCR) test is used for early 
detection and quantitation of human 
immunodeficiency virus in plasma of  HIV infected 
patients. This test is also helpful in deciding for 
switching to second-line ARV therapy and monitoring 
their prognostic response as well. In HIV infection, 
approximately 10 log10 virions of HIV are produced 
per day and a PCR test is used to detect this viral load 
in plasma of HIV-infected patients. AIDS will be 
developed in those HIV positive patients having very 
high plasma viral load and low CD4 lymphocytes.5 
The best and standard way of treatment for HIV 
infection is ARV therapy in the form of a three to the 
four-drug combination. The following are the main 
classes of ARV therapy: nucleoside, nucleotide, and 
non-nucleoside reverse transcriptase inhibitors and 
integrase inhibitors. They block the HIV genome 
replication process. Fusion inhibitors and C-
Chemokine Receptor (CCR5) antagonists work by 
blocking HIV viral entry into host cells. Protease 
inhibitors block the function of proteins that are vital 
for viral development. When these drugs are given in 
combination form, low viral levels can be maintained.6 
To achieve better responses, these drugs are given to 
HIV positive patients in the form of a regimen. The 
first-line regimen includes mostly two Non-Nucleoside 
Reverse Transcriptase Inhibitor (NNRTI) and one 
Nucleoside Reverse Transcriptase Inhibitor (NRTI) 
and 2nd line regimen include drugs that inhibit 
protease enzyme, which prevent cleavage of viral 
precursors. The most common 2nd line drug is Kaletra 
and the regimen include protease inhibitor+1 NRTI+1 
NNRTI.7 
The World Health Organization (WHO) recommends 
a first-line ARV therapy should consist of two 
nucleoside reverse transcriptase inhibitors and a non-
nucleoside reverse transcriptase inhibitor.8 The goal of 
treatment is to lower the plasma HIV RNA level and 
enhance CD4+ cell counts. Generally, 1-2 log decrease 
in viral load and an increase of CD4  immune cells per 
year is taken as an indication of positive drug effects.9 
ARV therapy provides more beneficial results when it 
is being initiated at a CD4 cell count of 500cells/ml 
instead of 350 cells/ml.10 
Keeping these in mind the present study was designed 
to see that after one year of starting ARV therapy, 
prognostic responses are checked by monitoring CD4 
cells count and HIV PCR testing in HIV-infected 
patients. The rationale of the study was to emphasize 
the importance of CD4 testing for initiating 
antiretroviral therapy in newly diagnosed HIV 
positive patients and the importance of both CD4 
testing and PCR testing in HIV positive patients who 
were on the first line and second line ARV therapy. 
 
Materials and Methods 
 
Prospective observational study design and Random 
sample technique were used in this study. For CD4 cell 
count, 3ml whole blood is taken in K3EDTA tubes (BD 
Diagnostics, USA). CD4  cell count was done by the 
FACSCALIBUR flow cytometer. A measured quantity 
of 20µL of Tritest CD4FITC/ CD8PE/ CD3PERCP 
reagent (BD Biosciences, USA) was added to the BD 
Trucount tm tube (BD Diagnostics, USA) containing 
beads and 50ul of whole blood added in it. The 
instrument was calibrated by running Calibritetm 3 
reagent (BD Biosciences, USA) with sheath fluid using 
BD Facscomp tm version 2.0 to set photomultiplier 
tubes (PMT) voltages, fluorescence compensation, to 
check instrument sensitivity and to adjust the 
threshold to minimize debris. Sample acquisition and 
analysis were done using MULTISET software. 
HIV RNA in plasma was quantified by polymerase 
chain reaction(PCR) Test. The Cobas Ampliprep and 
Cobas AMPLICOR HIV-1 MONITER test was used as 
automated PCR technology for the quantitative 
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detection of HIV-1 RNA in EDTA anticoagulated 
plasma. Its sensitivity is over range 50-1000000 
copies/ml.  
Automatic specimen preparation was done to extract 
HIV-1 RNA using the DNA probe capture technique. 
Reverse transcription of target RNA was done with the 
help of specific primers and rth polymerase. rth pol 
had both reverse transcriptase and DNA polymerase 
activity. Amplification of target complementary DNA 
was done using HIV-1 specific complementary 
primers. 
Automated denaturation did use, HIV-1DN4 
reagent(Roche Molecular Systems, USA), and 
detection is done using reagents HIV-1AD3, HIV-
1CN4, and  HIV-1 SB3 (Roche Molecular Systems, 
USA).Probes for detection of quantitation standard 
present in reagent HIV-1 SQ4(Roche Molecular 
Systems, USA). 
The inclusion criteria for the present study included 
those HIV-positive patients who had been confirmed 
HIV positive status by all three tests i.e Rapid test, 
ELISA test, and Western blot test. Only adults HIV 
positive patients, registered at HIV treatment and care 
centre in PIMS, Islamabad were selected. Patients of 
both gender age 30-40 years were selected.and  
Exclusion Criteria included HIV positive patients with 
age less than 30 years, HIV positive pregnant females, 




The data was entered on SPSS version 23. The 
quantitative data were presented as mean. The 
qualitative data were presented as a percentage. In this 
given statistics, no test of significance was applied. 
Among 276 HIV positive adult cases, 75% (n=207) 
were males and 25% (n=65) were females. 263 HIV 
patients were taking first-line ARV therapy. 
The number and percentages of adult HIV patients 
taking first-line Antiretroviral therapy had been 
shown in Table 1. Maximum HIV positive patients 











Table 1: Number of HIV Patients on first line 
Antiretroviral Therapy 
 
Baseline CD4 Cell count monitoring was done before 
the initiation of antiretroviral therapy. One year after 
the initiation of first-line ARV therapy, CD4 cell count 
was monitored. There were 84.5% (n=223) patients 
having  CD4+ cell count greater than 350 cells/uL and 
15.5% (n=40) patients having CD4+ cell count less than 
350 cells/uL as shown in Figure 1. THE mean CD4 cell 
count of patients on first-line ARV therapy was 361 
cells/UL and SD was  ± 181 of the mean value. 
 
Figure 1: CD4+ cell count of HIV positive patients on 
first-line ART 
 
The baseline viral load of HIV positive patients were 
not monitored. The viral load outcome of HIV positive 
patients was measured after one year of initiating first-
line antiretroviral therapy.  The mean outcome was 
88023. There were 182 patients having viral load 
<50copies/mL (69%). 81 patients had a viral load 




Regimen No. of Patients 
1 3TC+D4T 0.38% (n=01) 
2 3TC+ZDV 1.90% (n=05) 
3 EFV+3TC+D4T 11.40% (n=30) 
4 EFV+3TC+TNF 0.38% (n=01) 
5 EFV+3TC+ZDV 24.71% (n=65) 
6 EFV+ZLM 37.64% (n=99) 
7 NEVILAST40mg 0.76% (n=02) 
8 NFV+3TC+ZDV 0.38% (n=01) 
9 NVP+3TC+D4T 1.90% (n=05) 
10 NVP+3TC+ZDV 17.49% (n=46) 
11 NVP+ZLM 1.52% (n=4) 
12 Zidolam 1.52% (n=4) 
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Figure 2: Viral load of HIV positive patients on first-
line ART 
 
The number and percentages of adult HIV patients 
taking second-line Antiretroviral therapy had been 
shown in Table 2. 
Table 2: Number of HIV patients on second-line 
Antiretroviral Therapy 
There were 95.3% (n=263) HIV positive patients on 
first-line ARV therapy and 4.7% (n=13) patients were 
on second-line ARV therapy. Second-line ARV therapy 
was initiated only in those HIV positive patients who 
had failed to respond to first-line ARV therapy. Only 
13 out of 276 patients did not give a good response 
with first-line ARV therapy. Their mean CD4 Cell 




HIV and AIDS have become the most prevailing 
disease in Pakistan. ART is recommended for HIV 
infected patients. ART is the use of medicine to treat 
HIV infection. When taken in combination, HIV 
medicines can prevent the replication and 
transmission of the HIV virus. 
Awareness regarding HIV transmission, diagnosis, 
treatment, and ARV therapy prognosis comes with the 
establishment of different HIV and AIDS treatment 
centers in different regions of Pakistan. Patients 
registered in the PIMS centre until 2009 were observed 
to monitor CD4+ and viral load outcomes. 
All registered patients in centre were confirmed HIV 
positive cases. Most HIV patients were male. Age 
ranges from 30 to 40 years. CD4+ cell count and HIV 
PCR test was monitored in patients on first-line ARV  
and second-line antiretroviral therapy. Maximum 
numbers of HIV  patients were on the first-line 
combination of ARVs than second-line ARVs therapy. 
Their CD4+ cell count was monitored after one year, 
showing good CD4+ cells response to first-line ARVs. 
CD4 cell count increase in our study was 361 cells/ul. 
While in a study at ShriBhausaheb, Maharashtra, CD4 
cell count was monitored before and after initiation of 
ARV therapy. The mean CD4 count in 57 patients 
before initiation of ARV therapy was 222, and SD ± 
149 of the mean value. After 6 months of ARV therapy, 
the mean CD4 count increased to 306 and SD ± 178 of 
the mean value.1 
Adherence towards ART had been studied in 546 HIV 
positive Kenyan patients receiving HAART for up to 
228 months and found good adherence to ART. 65.8%  
of Patients showed HIV viral suppression with 
enhanced CD4 immune cells.11 
In the present study viral load of HIV  patients taking 
first-line ARV therapy was monitored one year after 
initiation of therapy. 67% of patients were having a 
viral quantity of fewer than 50 copies/mL showing 
good suppression of HIV in plasma against first-line 
ARV therapy. 
The virological outcome had been studied among sub-
Saharan African patients, virological success 
monitored at 12 months and 24 months since ART 
initiation was 87.7% and 83.7% respectively.12 
In an estimate from the study in Europe and the 
United States, the proportion of individuals with 
suppressed virological replication was greater for 
immediate universal cART initiation earlier in the 
follow-up. By 7 years, all strategies resulted in 
estimated proportions of virological suppression 
between 83% and 87%.13 
A study had been conducted in Thailand on people 
living with HIV aged 10-24 years who initiated ART 
from 2008 to 2013 through the Thai National AIDS 
Programme and who were followed up until 2014. At 
one year after initiating ART, 84% of patients showed 
good suppression and only 16% experienced 
Sr. 
Number 
Regimen No. of 
Patients 
1 KLT+3TC+D4T 7.69% (n=01) 
2 KLT+3TC+ZDV+DDI 7.69% (n=01) 
3 KLT+DDI+TNF 46.15% (06) 
4 KLT+DDI+ZLM 7.69% (n=01) 
5 KLT+TNF+D4T+3TC 7.69% (n=01) 
6 KLT+TNF+ZLM 15.38% (n=02) 
7 KLT+ZLM 7.69% (n=01) 
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virological failure. Their mean CD4 cell count was also 
raised from 190 cells to 310 cells/mm3.14 
Good response of CD4 cell count and RNA viremia 
towards HIV medicines depends upon the type of 
regimen taken by HIV patients. Some patients did not 
enhance their CD4+ cell count and showed no better 
viral response. They did not show response because of 
greater HIV replication and greater chances of viral 
mutation. That was the reason specific drugs against 
specific enzymes did not properly work, leading to 
poor prognosis of patients towards treatment. 
Maximum HIV positive patients had shown good 




First-line ARV therapy given to HIV positive patients 
proved itself best both in respect of increasing the 
immunity of HIV positive patients by increasing the 
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